Harmonization of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia

被引:233
作者
Bonifacio, Ezio [1 ]
Yu, Liping [2 ]
Williams, Alastair K. [3 ]
Eisenbarth, George S. [2 ]
Bingley, Polly J. [3 ]
Marcovina, Santica M. [4 ]
Adler, Kerstin [5 ]
Ziegler, Anette G. [5 ]
Mueller, Patricia W. [6 ]
Schatz, Desmond A. [7 ]
Krischer, Jeffrey P. [8 ]
Steffes, Michael W. [9 ]
Akolkar, Beena [10 ]
机构
[1] Deutsch Forsch Gemeinschaft Ctr Regenerat Therapi, D-01307 Dresden, Germany
[2] Univ Colorado, Barbara Davis Ctr Childhood Diabet, Denver, CO 80045 USA
[3] Univ Bristol, Southmead Hosp, Bristol BS10 5NB, Avon, England
[4] Univ Washington, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98109 USA
[5] Forschergrp Diabet eV, Diabet Res Inst, D-80804 Munich, Germany
[6] Ctr Dis Control & Prevent, Mol Risk Assessment Lab, Atlanta, GA 30341 USA
[7] Univ Florida, Ctr Diabet, Gainesville, FL 32610 USA
[8] Univ S Florida, Coll Med, Dept Pediat, Tampa, FL 33612 USA
[9] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[10] NIDDK, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
ANTIBODY STANDARDIZATION PROGRAM; TYPE-1; TRIALS; RISK;
D O I
10.1210/jc.2010-0293
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Rationale: Autoantibodies to islet antigen-2 (IA-2A) and glutamic acid decarboxylase (GADA) are markers for diagnosis, screening, and measuring outcomes in National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) consortia studies. A harmonization program was established to increase comparability of results within and among these studies. Methods: Large volumes of six working calibrators were prepared from pooled sera with GADA 4.8-493 World Health Organization (WHO) units/ml and IA-2A 2-235 WHO units/ml. Harmonized assay protocols for IA-2A and GADA using S-35-methionine-labelled in vitro transcribed and translated antigens were developed based on methods in use in three NIDDK laboratories. Antibody thresholds were defined using sera from patients with recent onset type 1 diabetes and healthy controls. To evaluate the impact of the harmonized assay protocol on concordance of IA-2A and GADA results, two laboratories retested stored TEDDY study sera using the harmonized assays. Results: The harmonized assays gave comparable but not identical results in the three laboratories. For IA-2A, using a common threshold of 5 DK units/ml, 549 of 550 control and patient samples were concordantly scored as positive or negative, specificity was greater than 99% with sensitivity 64% in all laboratories. For GADA, using thresholds equivalent to the 97th percentile of 974 control samples in each laboratory, 1051 (97.9%) of 1074 samples were concordant. On the retested TEDDY samples, discordance decreased from 4 to 1.8% for IA-2A (n = 604 samples; P = 0.02) and from 15.4 to 2.7% for GADA (n = 515 samples; P < 0.0001). Conclusion: Harmonization of GADA and IA-2A is feasible using large volume working calibrators and common protocols and is an effective approach to ensure consistency in autoantibody measurements. (J Clin Endocrinol Metab 95: 3360-3367, 2010)
引用
收藏
页码:3360 / 3367
页数:8
相关论文
共 16 条
  • [2] Diabetes antibody standardization program: First assay proficiency evaluation
    Bingley, PJ
    Bonifacio, E
    Mueller, PW
    [J]. DIABETES, 2003, 52 (05) : 1128 - 1136
  • [3] Optimized autoantibody-based risk assessment in family members - Implications for future intervention trials
    Bingley, PJ
    Williams, AJK
    Gale, EAM
    [J]. DIABETES CARE, 1999, 22 (11) : 1796 - 1801
  • [4] Effect of type 1 diabetes on the gender difference in coronary artery calcification: A role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) study
    Dabelea, D
    Kinney, G
    Snell-Bergeon, JK
    Hokanson, JE
    Eckel, RH
    Ehrlich, J
    Garg, S
    Hamman, RF
    Rewers, M
    [J]. DIABETES, 2003, 52 (11) : 2833 - 2839
  • [5] The World Health Organization International Collaborative Study for Islet Cell Antibodies
    Mire-Sluis, AR
    Das, RG
    Lernmark, Å
    [J]. DIABETOLOGIA, 2000, 43 (10) : 1282 - 1292
  • [6] SEARCH for Diabetes in Youth: a multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth
    Pettitt, DJ
    Bell, R
    Dabelea, D
    Dolan, L
    Imperatore, G
    Lawrence, JM
    Liese, AD
    Liu, LL
    Waitzfelder, B
    Rodriguez, BL
    Hillier, T
    Pihoker, C
    Hirsch, I
    Greenbaum, C
    Petitti, DB
    Kershnar, A
    Hamman, RF
    Klingensmith, GJ
    Rewers, M
    Krakoff, J
    Nash, PV
    Smith, CM
    Standiford, DA
    Daniels, SR
    Mayer-Davis, EJ
    Oeltmann, J
    Marcovina, S
    Aldrich, A
    Morgan, T
    Hardy, L
    Vestal, S
    Linder, B
    Engelgau, M
    Kahn, H
    Narayan, V
    Saaddine, J
    Valdez, R
    Williams, D
    [J]. CONTROLLED CLINICAL TRIALS, 2004, 25 (05): : 458 - 471
  • [7] Clinical presentation and treatment of type 2 diabetes in children
    Pinhas-Hamiel, Orit
    Zeitler, Phil
    [J]. PEDIATRIC DIABETES, 2007, 8 : 16 - 27
  • [8] The effect of the MHC locus on autoantibodies in type 1 diabetes
    Qu, H-Q
    Polychronakos, C.
    [J]. JOURNAL OF MEDICAL GENETICS, 2009, 46 (07) : 469 - 471
  • [9] The Environmental Determinants of Diabetes in the Young (TEDDY) Study TEDDY Study Group
    Rewers, Marian
    [J]. IMMUNOLOGY OF DIABETES V: FROM BENCH TO BEDSIDE, 2008, 1150 : 1 - 13
  • [10] HIGH-LEVEL OF CONCORDANCE BETWEEN ASSAYS FOR GLUTAMIC-ACID DECARBOXYLASE ANTIBODIES - THE FIRST INTERNATIONAL GLUTAMIC-ACID DECARBOXYLASE ANTIBODY WORKSHOP
    SCHMIDLI, RS
    COLMAN, PG
    BONIFACIO, E
    BOTTAZZO, GF
    HARRISON, LC
    ARNAIZVILLENA, A
    BAEKKESKOV, S
    BETTERLE, C
    BOSI, E
    BOUANANI, M
    DELAMAIRE, M
    DYRBERG, T
    EISENBARTH, G
    HAGOPIAN, W
    HUMBEL, RL
    KAUFMAN, D
    KOBAYASHI, T
    LERNMARK, A
    LESLIE, RDG
    MARSHALL, M
    NAGATAKI, S
    MULLER, C
    POWERS, A
    PAGANO, G
    PETERSEN, JS
    ROWLEY, MJ
    RAO, SV
    RICCIOTTI, R
    SCHERBAUM, W
    THIVOLET, C
    ZIEGLER, AG
    [J]. DIABETES, 1994, 43 (08) : 1005 - 1009